Company Analysis Puma Biotechnology, Inc.
1. Summary
Advantages
- The stock's return over the last year (107.83%) is higher than the sector average (-4.97%).
- Current debt level 34.73% is below 100% and has decreased over 5 years from 49.55%.
Disadvantages
- Price (6.24 $) is higher than fair price (5.09 $)
- Dividends (0%) are below the sector average (0.53%).
- The company's current efficiency (ROE=41.6%) is lower than the sector average (ROE=104.34%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Puma Biotechnology, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.6% | 4.6% | -1.6% |
| 90 days | 4.1% | -7% | 3% |
| 1 year | 107.8% | -5% | 21.9% |
PBYI vs Sector: Puma Biotechnology, Inc. has outperformed the "Healthcare" sector by 112.8% over the past year.
PBYI vs Market: Puma Biotechnology, Inc. has outperformed the market by 85.92% over the past year.
Stable price: PBYI is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: PBYI with weekly volatility of 2.07% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (6.24 $) is higher than the fair price (5.09 $).
Price is higher than fair: The current price (6.24 $) is 18.4% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (5.08) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (5.08) is higher than that of the market as a whole (-68.72).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.67) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (1.67) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0.67) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (0.67) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (3.3) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (3.3) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -40.81% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-40.81%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (41.6%) is lower than that of the sector as a whole (104.34%).
ROE vs Market: The company's ROE (41.6%) is higher than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (13.64%) is higher than that of the sector as a whole (-2.2%).
ROA vs Market: The company's ROA (13.64%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-32.16%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-32.16%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
